Kelun-Biotech jumps on progress of key product development

Sichuan Kelun-Biotech Biopharmaceutical

06/05/2024 06:03

** Shares of Sichuan Kelun-Biotech Biopharmaceutical
 6990.HK  jump 9.3% to HK$179.20, on course for the biggest
one-day pct rise since March 14, if gains hold
    ** Stock hits the highest since April 30, on track to snap
two sessions of fall
    ** The Chinese drug producer says its key product A400
(EP0031) for treatment of lung cancer has been cleared by the
United States Food and Drug Administration (FDA) to progress
into Phase 2 clinical development  
    ** Hong Kong's healthcare index  .HSCIH  climbs 0.9%, Hang
Seng Composite Index  .HSCI  gains 0.1% while Hang Seng Index
 .HSI  slips 0.1%
    ** Stock up 72.7% YTD  

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))